**AMENDMENTS TO THE CLAIMS:**

Please amend claims 1, 2, 5, 7 and 8, add claims 19-31, and cancel claim 9-18 without prejudice or disclaimer as follows. This listing of claims replaces all prior versions, and listings of claims, in the application.

**LISTING OF CLAIMS:**

1. (Currently amended) A combination of anti-gastrin-dependent tumor therapeutic ingredients, comprising:

(i) an immunogen directed against gastrin ~~dependent tumor growth~~; and

(ii) one or more chemotherapeutic agents.

2. (Currently amended) The combination of claim 1, wherein the immunogen comprises a therapeutically effective amount of an anti-gastrin-17 (G17) peptide-containing immunogen.

3. (Original) The combination according to claim 2, wherein the anti-gastrin G17 immunogen is conjugated to a Diphtheria toxoid.

4. (Original) The combination according to claim 2, wherein the anti-gastrin G17 immunogen further comprises a spacer peptide.

5. (Currently Amended) The combination ~~according to~~ of claim 2, wherein the anti-gastrin G17 immunogen comprises a peptide ~~consisting of~~ that has the sequence of amino ~~acid sequence~~ acid residues: pGlu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu as set forth in (SEQ ID NO. 1~~: in the Sequence Listing~~).

6. (Original) The combination according to claim 2, wherein the chemotherapeutic agent is selected from the group consisting of 5-fluorouracil, leucovorin, levamisole, cisplatin, tumor necrosis factor, and proglumide.

7. (Currently Amended) The combination of any ~~one~~ of ~~the~~ claims 1-6 ~~through 6~~, wherein each of the immunogen and the chemotherapeutic agents, comprise ~~further comprising~~ a pharmaceutically acceptable carrier.

8. (Currently amended) ~~Use of the~~ A method of treatment of a gastrin-dependent tumor, comprising administering the components of the combination of ~~combination claimed according to~~ any ~~one~~ of ~~the claims 1 through 7~~ claim 1 ~~for the treatment of a~~ to thereby treat a gastrin-dependent tumor in a patient.

9.-18. Cancelled.

19. (New) The method of claim 8 that comprises:

administering an anti-gastrin-17 (G17) immunogen to immunologically neutralize gastrin; and

administering an effective amount of one or more chemotherapeutic agents.

20. (New) The method of claim 19, wherein the immunogen comprises a gastrin G17-peptide.

21. (New) The method of claim 20, wherein the gastrin G17-peptide is conjugated to a diphtheria toxoid carrier.

22. (New) The method of claim 20, wherein the immunogen comprises the gastrin G17 peptide, a protein carrier and a spacer peptide that projects the gastrin G17-peptide away from the protein carrier and enhances capacity to bind lymphocyte receptors.

23. (New) The method of claim 19, wherein the gastrin G17-peptide comprises the sequence of amino acids set forth in SEQ ID NO.: 1.

24. (New) The method of claim 20, wherein the gastrin G17-peptide comprises the sequence of amino acids set forth in SEQ ID NO.: 1.

25. (New) The method of claim 19, wherein the chemotherapeutic agents are selected from among 5-fluorouracil, leucovorin, levamisole, cisplatin, tumor necrosis factor and proglumide.

26. (New) The method of claim 19, wherein the chemotherapeutic agent is 5-fluorouracil or leucovorin.

27. (New) The method of claim 19, wherein the anti-gastrin 17 immunogen is administered prior to administration of the chemotherapeutic agent.

28. (New) The method of claim 26, wherein the anti-gastrin 17 immunogen is administered prior to administration of the chemotherapeutic agent.

29. (New) The method of claim 19, wherein a chemotherapeutic agent is administered is administered in several cycles.

30. (New) The combination of claim 1, wherein the immunogen and one or more chemotherapeutic agents are in separate compositions.

31. (New) The combination of claim 1, wherein the immunogen and one or more chemotherapeutic agents are formulated in the same composition.